Uncategorized

Zymeworks adds lung disease drug, royalty deals in nearly $1B pick up of Theravance

Published

on

Zymeworks announced a new plan to become a royalty-driven company last year, making Theravance a perfect match.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version